Statistical methods in oncology trials
The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.
Hazard ratio
Log-rank test
Cochran-Mantel-Haenszel test
Odds ratio
Cox proportional-hazards model
Fisher exact test
Risk difference
Stratified log-rank test
All oncology trials
2,067 results
- Left Lateral Position Versus Supine Position in Colonoscopy: Complete Statistical AnalysisIndependent statistical analysis of Left Lateral Position Versus Supine Position in Colonoscopy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06664762).
- Lenalidomide (Revlimid) in Chronic Lymphocytic Leukemia (CLL): Complete Statistical AnalysisIndependent statistical analysis of Lenalidomide (Revlimid) in Chronic Lymphocytic Leukemia (CLL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00267059).
- Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non-Hodgkin’s Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non-Hodgkin's Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype: Complete Statistical AnalysisIndependent statistical analysis of Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Lenalidomide in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Lenalidomide in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Letrozole in Breast Cancer Who Have Received 5 Years of Aromatase Inhibitor Therapy: Complete Statistical AnalysisIndependent statistical analysis of Letrozole in Breast Cancer Who Have Received 5 Years of Aromatase Inhibitor Therapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Leuprolide Acetate or Goserelin Acetate With or Without Vismodegib Followed by Surgery in Treating Patients With Locally Advanced Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Leuprolide Acetate or Goserelin Acetate With or Without Vismodegib Followed by Surgery in Treating Patients With Locally Advanced Prostate Cancer: primary endpoint results, effect estimate with confidence interval,…
- LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids: Complete Statistical AnalysisIndependent statistical analysis of LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Lighting Intervention for Cancer-related Fatigue: Complete Statistical AnalysisIndependent statistical analysis of Lighting Intervention for Cancer-related Fatigue: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04827446).
- Linear Energy Transfer (LET)-Optimized Intensity Modulated Proton Therapy (IMPT) as a Component of Definitive Chemoradiation for Newly Diagnosed Squamous Cell Carcinoma of the Anal Canal: a Feasibility Trial: Complete Statistical AnalysisIndependent statistical analysis of Linear Energy Transfer (LET)-Optimized Intensity Modulated Proton Therapy (IMPT) as a Component of Definitive Chemoradiation for Newly Diagnosed Squamous Cell Carcinoma of the Anal Canal: a Feasibility Trial:…
- Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients: Complete Statistical AnalysisIndependent statistical analysis of Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab: Complete Statistical AnalysisIndependent statistical analysis of Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006): Complete Statistical AnalysisIndependent statistical analysis of Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03483103).
- LiveWellIndependent statistical analysis of DBT for Metastatic Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04973436).
- LOGICIndependent statistical analysis of LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- LOGRIBMETIndependent statistical analysis of Loss of Grip Strength, BMI, and Adjuvant Endocrine Therapy Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study: Complete Statistical AnalysisIndependent statistical analysis of Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Long-term Active Surveillance Study for Oral Contraceptives (LASS): Complete Statistical AnalysisIndependent statistical analysis of Long-term Active Surveillance Study for Oral Contraceptives (LASS): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00676065).
- Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004: Complete Statistical AnalysisIndependent statistical analysis of Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- LOTIS-9Independent statistical analysis of A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL): primary endpoint results, effect estimate with confidence interval, sample-size…
- Lovastatin in Treating Patients At High Risk of Melanoma: Complete Statistical AnalysisIndependent statistical analysis of Lovastatin in Treating Patients At High Risk of Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00462280).
- Low Dose Arsenic Trioxide as a Potential Chemotherapy Protector: Complete Statistical AnalysisIndependent statistical analysis of Low Dose Arsenic Trioxide as a Potential Chemotherapy Protector: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01428128).
- Low-Dose Prednisone or Methylprednisolone in Treating Patients With Newly Diagnosed Acute Graft-versus-Host Disease: Complete Statistical AnalysisIndependent statistical analysis of Low-Dose Prednisone or Methylprednisolone in Treating Patients With Newly Diagnosed Acute Graft-versus-Host Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Low-Dose Radiation Therapy to the Whole Liver With Gemcitabine and Cisplatin in IHC: Complete Statistical AnalysisIndependent statistical analysis of Low-Dose Radiation Therapy to the Whole Liver With Gemcitabine and Cisplatin in IHC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Lower Dose Chemotherapy Given More Frequent With Avastin to Treat Advanced Non-Squamous Non-Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Lower Dose Chemotherapy Given More Frequent With Avastin to Treat Advanced Non-Squamous Non-Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- LSA4 Protocol for the Treatment of Advanced Pediatric and Adolescent Non-Hodgkins Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of LSA4 Protocol for the Treatment of Advanced Pediatric and Adolescent Non-Hodgkins Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- LUDICASIndependent statistical analysis of Characteristics of Sexual Dysfunction in Patients With Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06018376).
- LUME-Lung 1Complete statistical analysis of LUME-Lung 1, the phase 3 randomized trial of BIBF 1120 plus docetaxel versus placebo plus docetaxel in second-line non-small cell lung cancer, including time-to-event, response, disease-control, quality-of-life, and…
- LUME-Lung 2Independent statistical analysis of LUME-Lung 2, a randomized phase 3 trial of nintedanib plus pemetrexed versus placebo plus pemetrexed in second-line nonsquamous non-small-cell lung cancer, including progression-free survival, overall survival, response, disease…
- LUME-Lung 3Independent statistical analysis of LUME-Lung 3 (NCT01346540), a randomized phase 1 trial evaluating nintedanib added to gemcitabine/cisplatin in first-line NSCLC with squamous cell histology.
- Lung Cancer Screening Eligibility Assessment: Complete Statistical AnalysisIndependent statistical analysis of Lung Cancer Screening Eligibility Assessment: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06133816).
- Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer: primary endpoint results, effect estimate with confidence…
- LuPSMAIndependent statistical analysis of the LuPSMA phase 2 randomized trial evaluating flexible dosing of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer, including design, endpoints, planned methodology, and statistical interpretation.
- LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures: Complete Statistical AnalysisIndependent statistical analysis of LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- LUX-Lung 6Independent statistical analysis of LUX-Lung 6, the randomized phase 3 trial comparing afatinib with gemcitabine-cisplatin chemotherapy in first-line non-small cell lung cancer. Includes progression-free survival, response, overall survival, quality-of-life endpoints, statistical methods,…
- LUX-Lung 7Independent statistical analysis of LUX-Lung 7, the randomized phase 2 trial comparing afatinib with gefitinib in first-line EGFR mutation-positive lung adenocarcinoma, including survival, response, quality-of-life, and safety analyses.
- M-RePoRTIndependent statistical analysis of Metformin for Rising PSA Remote Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02376166).
- M032-HSV-1Independent statistical analysis of Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant Glioma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- M14-032Independent statistical analysis of M14-032, a phase 2 single-group study of venetoclax in chronic lymphocytic leukemia after relapse or refractory disease following B-cell receptor signaling pathway inhibitor therapy.
- M3541 in Combination With Radiotherapy in Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of M3541 in Combination With Radiotherapy in Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03225105).
- M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC): Complete Statistical AnalysisIndependent statistical analysis of M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- MA.17Independent statistical analysis of MA.17, a randomized phase 3 trial evaluating letrozole versus placebo in women with breast cancer who had received 5 years of aromatase inhibitor therapy, including disease-free survival, overall…
- MADIndependent statistical analysis of Magnetic Anastomosis Device Relief of Malignant Gastric Outlet Obstruction: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00487552).
- MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation: Complete Statistical AnalysisIndependent statistical analysis of MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- MAGE-A4ᶜ¹º³²T for Multi-Tumor: Complete Statistical AnalysisIndependent statistical analysis of MAGE-A4ᶜ¹º³²T for Multi-Tumor: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03132922).
- MAGNET (Magnetically Controlled Capsule for Assessment of Gastric Mucosa in Symptomatic Patients): Complete Statistical AnalysisIndependent statistical analysis of MAGNET (Magnetically Controlled Capsule for Assessment of Gastric Mucosa in Symptomatic Patients): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…